Products Categories
| CAS No.: | 54-31-9 |
|---|---|
| Name: | Furosemide |
| Molecular Structure: | |
|
|
|
| Formula: | C12H11ClN2O5S |
| Molecular Weight: | 330.749 |
| Synonyms: | Frumide;Urex-M;Diurin;Uritol;Frusedan;Prefemin;5-(Aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid;Depix;Mirfat;Furosix;Aquarid;Chlor-N- (2-furylmethyl)-5-sulfamylanthranilsaeure;Bioretic;4-chloro-2-(2-furylmethylamino)-5-sulfamoyl-benzoic acid;Neo-renal;Furosifar;Puresis;Furosan;Furex;Rusyde;Jenafusid;Aldic;Urian;Furanthril; |
| EINECS: | 200-203-6 |
| Density: | 1.606 g/cm3 |
| Melting Point: | 220 °C |
| Boiling Point: | 582.1 °C at 760 mmHg |
| Flash Point: | 305.9 °C |
| Solubility: | Soluble in acetone, DMF or methanol. Slightly soluble in water |
| Appearance: | white to light yellow crystal powder |
| Hazard Symbols: |
 T,  F,  Xi
|
| Risk Codes: | 61-39/23/24/25-11 |
| Safety: | 7-16-45-53-36/37/39-22 |
| Transport Information: | UN 1230 3/PG 2 |
| PSA: | 131.01000 |
| LogP: | 3.74480 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 548773-13-32-amino-4,6-dimethylpyrimidine-5-carboxylic acid
- 617-88-9
2-Chloromethylfuran
- 3086-91-7
4-chloro-5-sulfamoylanthranilic acid
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| With potassium bromide In N,N-dimethyl-formamide at 120℃; for 24h; Reagent/catalyst; Solvent; Temperature; | 97% |
- 4793-48-0
methyl 4-chloro-2-[((furan-2-yl)methyl)amino]-5-sulfamoylbenzoate
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| With water; sodium hydroxide In ethanol at 20℃; | 88.5% |
- 617-89-0
furan-2-ylmethanamine
- 2736-23-4
2,4-dichloro-5-sulfamoylbenzoic acid
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| With sodium hydrogencarbonate In dimethyl sulfoxide at 130℃; for 6h; Solvent; Inert atmosphere; | 71.2% |
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| With bile at 37℃; Kinetics; Further Variations:; Reagents; Decomposition; |
B
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| With water at 37℃; Kinetics; Further Variations:; pH-values; Hydrolysis; |
- 2736-23-4
2,4-dichloro-5-sulfamoylbenzoic acid
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1.1: sodium ethanolate; pyrographite / ethanol / 2 h / 40 °C 2.1: ethylene glycol / 3 h / 130 - 135 °C 3.1: water / 0.5 h / 65 °C 3.2: 3 h / 0 - 5 °C / pH 3.5 - 4 View Scheme |
- 41733-55-5
4-chloro-N-(2-furfuryl)-5-sulfamoylanthranilic acid sodium salt
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| Stage #1: 4-chloro-N-(2-furfuryl)-5-sulfamoylanthranilic acid sodium salt In water at 65℃; for 0.5h; Stage #2: With acetic acid In water at 0 - 5℃; for 3h; pH=3.5 - 4; |
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| Stage #1: C36H47Br2ClN2O13S With N-ethyl-N,N-diisopropylamine In water; acetonitrile for 1.25h; Sonication; Stage #2: In water; acetonitrile at 20℃; for 72h; Reagent/catalyst; Temperature; |
- 56447-54-2
4-chloro-2-fluoro-5-chlorosulfonylbenzoic acid
- 54-31-9
4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: triethylamine; ammonia / tetrahydrofuran / 16 h / 0 - 20 °C 2: N-ethyl-N,N-diisopropylamine / 1,2-dimethoxyethane / 16 h / 130 °C View Scheme |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: chlorosulfonic acid / 0 - 140 °C 2: triethylamine; ammonia / tetrahydrofuran / 16 h / 0 - 20 °C 3: N-ethyl-N,N-diisopropylamine / 1,2-dimethoxyethane / 16 h / 130 °C View Scheme |
- 93-14-1Guaifenesin
- 5571-36-8Estradiene dione-3-keta
- 723-46-6Sulfamethoxazole
- 67-47-02-Furancarboxaldehyde,5-(hydroxymethyl)-
- 3286-46-2Sulbutiamine
- 4075-81-4Propanoicacid, calcium salt (2:1)
- 25812-30-0Gemfibrozil
- 81403-68-1Alfuzosin hydrochloride
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Chemistry
Molecular Structure:
Molecular Formula: C12H11ClN2O5S
Molecular Weight: 330.7441
IUPAC Name: 4-Chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
Synonyms of Furosemide (CAS NO.54-31-9): Furosemide [USAN:INN:JAN] ; Frumil ; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid ; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid ; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid ; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid ; 5-(Aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoic acid ; Aisemide ; Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)- ; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure ; Disemide ; EINECS 200-203-6 ; Golan ; Hydroled ; Jenafusid ; Katlex ; Lasix Retard ; Marsemide ; Novosemide ; Prefemin ; Radisemide ; Selectofur ; Urosemide ; Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-
CAS NO: 54-31-9
Classification Code: Diuretic ; Diuretics ; Drug / Therapeutic Agent ; Human Data ; Membrane Transport Modulators ; Mutation data ; Natriuretic Agents ; Reproductive Effect ; Sodium Potassium Chloride Symporter Inhibitors ; Tumor data
H bond acceptors: 7
H bond donors: 4
Freely Rotating Bonds: 5
Polar Surface Area: 88.44 Å2
Index of Refraction: 1.657
Molar Refractivity: 75.76 cm3
Molar Volume: 205.8 cm3
Surface Tension: 75.2 dyne/cm
Density: 1.606 g/cm3
Flash Point: 305.9 °C
Enthalpy of Vaporization: 91.55 kJ/mol
Boiling Point: 582.1 °C at 760 mmHg
Vapour Pressure: 2.15E-14 mmHg at 25°C
Melting point: 220 °C
Storage temp: 2-8°C
Appearance: white to light yellow crystal powder
Sensitivity: Light and Air sensitive.
Water solubility: Slightly soluble in water.
Stability: Stable, but light sensitive, air sensitive and hygroscopic. Incompatible with strong oxidizing agents.
Uses
Furosemide (CAS NO.54-31-9) is used as a diuretic and blood pressure reducer and it is sometimes used in the management of severe hypercalcemia in combination with adequate rehydration. As a loop diuretic, Furosemide is used in the treatment of congestive heart failure and edema. Besides, it has also been used to prevent thoroughbred and standardbred race horses from bleeding through the nose during races. And along with some other diuretics, Furosemide(54-31-9) is also included on the World Anti-Doping Agency's banned drug list because of its alleged use as a masking agent for other drugs.
Production
Furosemide (CAS NO.54-31-9) is prepared by treating 2,4,5-trichlorobenzoic acid with chlorosulfonic acid, and fur-ther treatment with ammonia and furfuryl amine. Furosemide can also be synthesized stating with 2,4-dichlorobenzoic acid (formed by chlorination and oxidation of toluene). Reaction with chlorosulfonic acid is an electrophilic aromatic substitution via the species -SO,Cl- attacking ortho and para to the chlorines and meta to the carboxylate. Ammonolysis to the sulfonamide is followed by nucleophilic aromatic substitution of the loss hindered chlorine by furfurylamine (obtained from furfural-a product obtained by the hydrolysis of carbohydrates).
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | > 400mg/kg (400mg/kg) | Drugs in Japan Vol. 6, Pg. 725, 1982. | |
| dog | LD50 | oral | 2gm/kg (2000mg/kg) | Drugs in Japan Vol. 6, Pg. 725, 1982. | |
| human | TDLo | intravenous | 1300ug/kg (1.3mg/kg) | CARDIAC: OTHER CHANGES VASCULAR: REGIONAL OR GENERAL ARTERIOLAR CONSTRICTION | Annals of Internal Medicine. Vol. 103, Pg. 1, 1985. |
| infant | TDLo | intravenous | 1mg/kg/4H-I (1mg/kg) | Archives of Disease in Childhood. Vol. 59, Pg. 907, 1984. | |
| man | TDLo | intravenous | 29mg/kg (29mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR SENSE ORGANS AND SPECIAL SENSES: TINNITUS: EAR KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED | New England Journal of Medicine. Vol. 282, Pg. 1413, 1970. |
| mouse | LD50 | intravenous | 308mg/kg (308mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 14, Pg. 44, 1964. | |
| mouse | LD50 | oral | 2gm/kg (2000mg/kg) | European Patent Application. Vol. #0008367, | |
| mouse | LD50 | unreported | 900mg/kg (900mg/kg) | European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 15, Pg. 386, 1980. | |
| rabbit | LD50 | intravenous | 400mg/kg (400mg/kg) | Drugs in Japan Vol. 6, Pg. 725, 1982. | |
| rabbit | LD50 | oral | 800mg/kg (800mg/kg) | Drugs in Japan Vol. 6, Pg. 725, 1982. | |
| rat | LD50 | intraperitoneal | 800mg/kg (800mg/kg) | Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 42, Pg. 199, 1985. | |
| rat | LD50 | intravenous | 800mg/kg (800mg/kg) | Drugs in Japan Vol. 6, Pg. 725, 1982. | |
| rat | LD50 | oral | 2600mg/kg (2600mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
| rat | LD50 | subcutaneous | 4600mg/kg (4600mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967. | |
| women | TDLo | intravenous | 2500ug/kg/2M- (2.5mg/kg) | CARDIAC: PULSE RATE | Intensive Care Medicine. Vol. 12, Pg. 54, 1986. |
| women | TDLo | oral | 6250ug/kg (6.25mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS | Journal of Toxicology, Clinical Toxicology. Vol. 31, Pg. 341, 1993. |
| women | TDLo | oral | 120mg/kg/21W- (120mg/kg) | KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS | Journal of the Royal Society of Medicine. Vol. 79, Pg. 239, 1986. |
Safety Profile
Hazard Codes of Furosemide (CAS NO.54-31-9): 
T
F
Risk Statements: 61-39/23/24/25-11
61: May cause harm to the unborn child
39/23/24/25: Toxic: danger of very serious irreversible effects through inhalation, in contact with skin and if swallowed
11: Highly Flammable
Safety Statements: 7-16-45-53-36/37/39-22
7: Keep container tightly closed
16: Keep away from sources of ignition - No smoking
45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
53: Avoid exposure - obtain special instruction before use
36/37/39: Wear suitable protective clothing, gloves and eye/face protection
22: Do not breathe dust
RIDADR: UN 1230 3/PG 2
WGK Germany: 3
RTECS: CB2625000
Specification
Furosemide may undergo hydrolysis at sufficiently low pH. The pH of aqueous solutions should be maintained in the basic range to prevent hydrolysis. Alcohol has been shown to improve the stability of Furosemide. Incompatible with strong oxidizing agents .